KIT and mesothelioma: From a preclinical point of view, mesothelioma cell lines may overexpress PDGFRB, and the combination of gemcitabine and imatinib, a multikinase inhibitor targeting KIT, BCR-ABL fusion protein and PDGFRB, induced cell death and reduced tumor growth in cellular lines [76] and xenografted murine models of mesothelioma overexpressing PDFGRB [77].